These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36449471)

  • 21. Defining utility values for patients with tardive dyskinesia.
    Ayyagari R; Goldschmidt D; Zhou M; Ribalov R; Caroff SN; Leo S
    Curr Med Res Opin; 2022 Mar; 38(3):401-407. PubMed ID: 35045768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tardive dyskinesia: Who gets it and why.
    Frei K
    Parkinsonism Relat Disord; 2019 Feb; 59():151-154. PubMed ID: 30522959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identifying Tardive Dyskinesia: Risk Factors, Functional Impact, and Diagnostic Tools.
    Saklad SR
    J Clin Psychiatry; 2020 Jan; 81(1):. PubMed ID: 31944066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How to Assess Tardive Dyskinesia Symptom Improvement With Measurement-Based Care.
    McEvoy JP
    J Clin Psychiatry; 2020 Nov; 81(6):. PubMed ID: 33147658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical management of tardive dyskinesia: Five steps to success.
    Citrome L
    J Neurol Sci; 2017 Dec; 383():199-204. PubMed ID: 29246613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice.
    Hauser RA; Meyer JM; Factor SA; Comella CL; Tanner CM; Xavier RM; Caroff SN; Lundt L
    CNS Spectr; 2022 Apr; 27(2):208-217. PubMed ID: 33213556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Crushing deutetrabenazine for treatment of tardive dyskinesia in a patient with severe orofacial symptoms: A case report.
    Wietholter JP; Sizemore J; Piechowski K
    Am J Health Syst Pharm; 2020 Sep; 77(18):1477-1481. PubMed ID: 32761113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 4: Case Report Data.
    Macaluso M; Flynn A; Preskorn S
    J Psychiatr Pract; 2016 May; 22(3):203-20. PubMed ID: 27123800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders.
    McEvoy J; Park T; Schilling T; Terasawa E; Ayyagari R; Carroll B
    Curr Med Res Opin; 2019 Jul; 35(7):1205-1214. PubMed ID: 30638073
    [No Abstract]   [Full Text] [Related]  

  • 30. A Cross-Sectional Study on the Characteristics of Tardive Dyskinesia in Patients with Chronic Schizophrenia.
    Huang Y; Pan L; Teng F; Wang G; Li C; Jin L
    Shanghai Arch Psychiatry; 2017 Oct; 29(5):295-303. PubMed ID: 29276353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Revisiting Tardive Dyskinesia: Focusing on the Basics of Identification and Treatment.
    Citrome L; Saklad SR
    J Clin Psychiatry; 2020 Feb; 81(2):. PubMed ID: 32078259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Future directions in tardive dyskinesia research.
    Meyer JM
    J Neurol Sci; 2018 Jun; 389():76-80. PubMed ID: 29433809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tardive dyskinesia in Chinese patients with schizophrenia: Prevalence, clinical correlates and relationship with cognitive impairment.
    Liang Q; Wang D; Zhou H; Chen D; Xiu M; Cui L; Zhang X
    J Psychiatr Res; 2022 Jul; 151():181-187. PubMed ID: 35489178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deutetrabenazine in the treatment of tardive dyskinesia.
    Niemann N; Jimenez-Shahed J
    Neurodegener Dis Manag; 2019 Apr; 9(2):59-71. PubMed ID: 30702019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
    Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients.
    Witter DP; Holbert RC; Suryadevara U
    Expert Opin Pharmacother; 2017 Jul; 18(10):965-972. PubMed ID: 28443349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence, clinical correlates and risk factors associated with Tardive Dyskinesia in Chinese patients with schizophrenia.
    Uludag K; Wang DM; Goodman C; Chen DC; Wang L; Zhang X
    Asian J Psychiatr; 2021 Dec; 66():102877. PubMed ID: 34638091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine.
    Hauser RA; Barkay H; Wilhelm A; Wieman M; Savola JM; Gordon MF
    Parkinsonism Relat Disord; 2022 Apr; 97():47-51. PubMed ID: 35299070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
    Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tardive Dyskinesia: Recognition, Patient Assessment, and Differential Diagnosis.
    Jain R; Correll CU
    J Clin Psychiatry; 2018; 79(2):. PubMed ID: 29570969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.